Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated May 3, 2023 (3 years ago)

Pin-Away PYRENTAL PAMOATE

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Use of non-food grade lubricant in mixing vessel.

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Pin-Away PYRENTAL PAMOATE (Pyrantel base 50 mg / mL) Pinworm Treatment, 2 FL OZ (60 mL) bottle, Distributed by: Cara Incorporated, 333 Strawberry Field Road, Warwick, RI 05886. NDC 70309-080-02

Affected NDC 70309-0080-02

Compare with the code on your package — it is the most precise check available.

Recalling firm
Denison Pharmaceuticals, LLC
NDC code
70309-080-02
Origin
RI, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0774-2023 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other recalls by Denison Pharmaceuticals, LLC

All 2023 recalls
Class II · Moderate risk

Zapzyt

Chemical Contamination: Presence of benzene.

Ongoing Chemical / undeclared Denison Pharmaceuticals, LLC NDC 71687-0011-1 D-0273-2025
Class III · Low risk

Kids' Cough and Chest Congestion

Crystallization: Lack of uniformity - a change in texture, chunky, grainy, and small crystal substances inside the bottles.

Ongoing Failed specification Denison Pharmaceuticals, LLC D-0034-2025
Class III · Low risk

Adult Cough and Chest Congestion

Crystallization: Lack of uniformity - a change in texture, chunky, grainy, and small crystal substances inside the bottles.

Ongoing Failed specification Denison Pharmaceuticals, LLC D-0033-2025

Other cgmp deviation recalls from 2023

All cgmp deviation recalls
Class II · Moderate risk

Sertraline Tablets

CGMP Deviations: Inadequate line clearance which may result in a potential comingling of product.

Ongoing cGMP deviation Legacy Pharmaceutical Packaging LLC NDC 68645-523-54 D-0205-2024
Class II · Moderate risk

Oxygen

cGMP Deviations

Terminated cGMP deviation Family Medical Supply Inc D-0106-2024
Class III · Low risk

V-FORCE Homeopathic

Incorrect Product Formulation: product contains Active Ingredient Glandula Suprarenalis Suis 8X instead of Glandula Suprarenalis Bovine 8X (as stated on the product label).

Terminated cGMP deviation Grato Holdings, Inc. D-0099-2024
Class II · Moderate risk

Strong Iodine Solution U.S.P.

CGMP Deviations: Recall due to the absence of USP CGMP compendial requirements.

Terminated cGMP deviation Safecor Health, LLC NDC 48433-230-15 D-0082-2024